BillionToOne, Inc.
Rank #237HypergrowthBLLN · Nasdaq · Healthcare
BillionToOne, Inc. (BLLN) — Rank #237 by gross profitability (GP/assets 0.29) · ROE 1.4% · Piotroski F-Score 7 / 9.
As-of 2026-09-15 · CIK 0002070849 · all metrics point-in-time as of the filing date.
About
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics.
Show moreShow less
The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc.
was incorporated in 2016 and is headquartered in Menlo Park, California.
- Industry
- Diagnostics & Research
- Sector
- Healthcare
- State
- DE
- Filer Category
- Non-accelerated filerEmerging growth company
- Fiscal Year End
- December 31
- Website
- billiontoone.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-03-11 | 2024-12-31filed 2026-03-11 | 2023-12-31filed 2026-03-11 |
|---|---|---|---|
| Operating | |||
| Depreciation & amortization | 6.9 | 7.0 | 5.9 |
| Stock-based compensation | 15.9 | 8.4 | 4.9 |
| Change in receivables | 16.9 | 15.6 | 2.6 |
| Change in inventory | 8.8 | 1.5 | 1.4 |
| Change in payables | 1.8 | 0.9 | 0.2 |
| Operating cash flow | 24.6 | (41.4) | (53.7) |
| Investing | |||
| Capital expenditures | 8.9 | — | — |
| Investing cash flow | (8.9) | (5.4) | 82.8 |
| Financing | |||
| Debt issued | 0.0 | 49.8 | 15.0 |
| Debt repaid | 0.0 | 35.0 | 0.0 |
| Share repurchases | 0.0 | 0.5 | 0.0 |
| Financing cash flow | 288.8 | 141.0 | 13.4 |
| Summary | |||
| Free cash flow | 15.7 | 15.7 | 15.7 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?